8215 Westchester Dr Suite 221, Dallas, TX 75225 (214)3612772 (Phone), (214)3619968 (Fax)
Certifications:
Physical Medicine & Rehabilitation
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
8215 Westchester Dr Suite 221, Dallas, TX 75225
Medical Center of Arlington 3301 Matlock Road, Arlington, TX 76015
Education:
Medical School Tongji Med University Medical School St Barnabas Med Center Graduated: 2007 Medical School University Of Texas Southwestern Med School Graduated: 2010
Health South Rehabilitation Hospital 7930 Northaven Rd, Dallas, TX 75230 (214)7068200 (phone), (214)7068380 (fax)
Star Health & Rehab PA 6715 Pemberton Dr, Dallas, TX 75230 (214)8087704 (phone), (214)9871475 (fax)
Education:
Medical School Tongji Med Univ, Wuhan City, Hubei, China Graduated: 1982
Languages:
English
Description:
Dr. Zhang graduated from the Tongji Med Univ, Wuhan City, Hubei, China in 1982. She works in Dallas, TX and 1 other location and specializes in Physical Medicine & Rehabilitation.
Ling Zhang - Missouri City TX, US Daniel A. Aguilar - Lake Jackson TX, US Debkumar Bhattacharjee - Blue Bell PA, US William A. Koonce - Pearland TX, US Basudeb Saha - Missouri City TX, US
Assignee:
DOW GLOBAL TECHNOLOGIES LLC - Midland MI
International Classification:
C07F 7/02 C08G 18/73 C08G 18/71
US Classification:
528 67, 528 75, 556444
Abstract:
Embodiments of the invention provide for a method of producing a silylated polyoxyalkylene polymer having at least one crosslinkable silyl group and at least one hydroxyl group in each molecule. The method comprises providing a polyoxyalkylene polymer having at least one unsaturated group and at least one alcoholic hydroxyl group in each molecule, wherein the polyoxyalkylene polymer includes an impurity double metal cyanide complex mixed therein, and wherein the polyoxyalkylene polymer has not been treated with a metal-coordinating compound; and adding to the polyoxyalkylene polymer a compound having a hydrogen-silicon bond and a crosslinkable silyl group in each molecule and a hydrosilylation catalyst to thereby carry out a hydrosilylation reaction, wherein the hydrosilyation reaction is performed in an absence of a metal-coordinating compound.
Ling Zhang - Missouri City TX, US Kamesh R. Vyakaranam - Pearland TX, US Sara Arshad - West Springfield MA, US William A. Koonce - Pearland TX, US
Assignee:
DOW GLOBAL TECHNOLOGIES LLC - Midland MI
International Classification:
C08G 18/38
US Classification:
524590, 525460
Abstract:
Embodiment of the invention provide for compositions having at least one crosslinkable silyl group in each molecule. The crosslinkable silane-terminated polymer may include a reaction product of at least a polyol having a nominal functionality of at least 2 and a isocyanate capped hydrosilylated polymer. The isocyanate capped hydrosilylated polymer may include a reaction product of at least one isocyanate and a hydrosilylated polymer. The hydrosilylated polymer may include a reaction product of a the reaction of at least a) a polymer having at least one unsaturated group and at least one alcoholic hydroxyl group in each molecule and having a number average molecular weight of between about 100 and about 5000 and b) a compound having a hydrogen-silicon bond and a crosslinkable silyl group in each molecule.
Kamesh R. Vyakaranam - Pearland TX, US Ling Zhang - Missouri City TX, US William A. Koonce - Pearland TX, US Juan Carlos Medina - Lake Jackson TX, US Ganesh Kailasam - Pearland TX, US Rajat Duggal - Pearland TX, US Nathan Wilmot - Missouri City TX, US
Assignee:
DOW GLOBAL TECHNOLOGIES LLC - Midland MI
International Classification:
C08G 18/22 C08G 18/38
US Classification:
524588, 528 28, 528 15, 528 21, 528 23, 528 13
Abstract:
Embodiments of the invention provide for methods of producing a composition comprising a crosslinkable silane-terminated polymer having at least one crosslinkable silyl group in each molecule. The method comprises providing a polymer having at least one unsaturated group and at least one alcoholic hydroxyl group in each molecule, adding to the polymer a compound having a hydrogen-silicon bond and a crosslinkable silyl group in each molecule and a hydrosilylation catalyst to thereby carry out a hydrosilylation reaction to form a composition comprising hydrosilylated polyoxyalkylene polymers, reacting the hydrosilylated polyoxyalkylene polymers with at least one isocyanate in the presence of a first tin-free catalyst to form an isocyanate reacted hydrosilylated polymer, and optionally reacting the isocyanate reacted hydrosilylated polymer with a polyol having a nominal functionality of at least 2 to form a polyol reacted crosslinkable silane-terminated polymer.
Kameswara R. Vyakaranam - Pearland TX, US Ling Zhang - Missouri City TX, US William A. Koonce - Pearland TX, US Sara Arshad - West Springfield MA, US Venkat S. Minnikanti - Pearland TX, US Dwight D. Latham - Clute TX, US Phillip S. Athey - Lake Jackson TX, US
Assignee:
DOW GLOBAL TECHNOLOGIES LLC - Midland MI
International Classification:
C08G 18/70
US Classification:
528 29
Abstract:
Embodiments of the invention provide for compositions including a crosslinkable silane-terminated polymer having at least one crosslinkable silyl group in each molecule. The crosslinkable silane-terminated polymer comprises a reaction product of at least a isocyanate capped hydrosilylated polymer and a polyol having a nominal functionality of at least 2 which is at least one of a polycarbonate polyol, a natural oil based polyol, a polyoxyalkyleneamine, a difunctional aromatic amine, a polybutyloxide polyether polyol, and a polytetramethylene glycol.
Human Application Of Engineered Chimeric Antigen Receptor (Car) T-Cells
- Austin TX, US Hiroki TORIKAI - Houston TX, US Ling ZHANG - Houston TX, US Helen HULS - Houston TX, US Lenka HURTON - Houston TX, US Simon OLIVARES - Houston TX, US Janani KRISHNAMURTHY - Houston TX, US
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
Human Application Of Engineered Chimeric Antigen Receptor (Car) T-Cells
- Austin TX, US Hiroki TORIKAI - Houston TX, US Ling ZHANG - Houston TX, US Helen HULS - Houston TX, US Lenka HURTON - Houston TX, US Simon OLIVARES - Houston TX, US Janani KRISHNAMURTHY - Houston TX, US
International Classification:
A61K 39/00 C07K 14/705 C07K 14/725 C07K 16/30
Abstract:
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
Human Application Of Engineered Chimeric Antigen Receptor (Car) T-Cells
- Austin TX, US Hiroki TORIKAI - Houston TX, US Ling ZHANG - Houston TX, US Helen HULS - Houston TX, US Lenka HURTON - Houston TX, US Simon OLIVARES - Houston TX, US Janani KRISHNAMURTHY - Houston TX, US
International Classification:
A61K 35/17 C07K 14/54
Abstract:
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
- Midland MI, US Ling Zhang - Missouri City TX, US William A. Koonce - Pearland TX, US Juan Carlos Medina - Lake Jackson TX, US Ganesh Kailasam - Pearland TX, US Rajat Duggal - Pearland TX, US Nathan Wilmot - Missouri City TX, US
International Classification:
C08G 18/50 C08G 18/20 C08G 18/22 C08G 18/76
US Classification:
528 19, 528 28, 528 21
Abstract:
Embodiments of the invention provide for methods of producing a composition comprising a crosslinkable silane-terminated polymer having at least one crosslinkable silyl group in each molecule. The method comprises providing a polymer having at least one unsaturated group and at least one alcoholic hydroxyl group in each molecule, adding to the polymer a compound having a hydrogen-silicon bond and a crosslinkable silyl group in each molecule and a hydrosilylation catalyst to thereby carry out a hydrosilylation reaction to form a composition comprising hydrosilylated polyoxyalkylene polymers, reacting the hydrosilylated polyoxyalkylene polymers with at least one isocyanate in the presence of a first tin-free catalyst to form an isocyanate reacted hydrosilylated polymer, and optionally reacting the isocyanate reacted hydrosilylated polymer with a polyol having a nominal functionality of at least 2 to form a polyol reacted crosslinkable silane-terminated polymer.
Ling Zhang, the first author of the paper, exposed mice to S. aureus and within hours detected a major increase in both the number and size of fat cells at the site of infection. More importantly, these fat cells produced high levels of an antimicrobial peptide (AMP) called cathelicidin antimicrobia
aureus in the fat layer of the skin, so researchers looked to see if the subcutaneous fat played a role in preventing skin infections.Ling Zhang, PhD, the first author of the paper, exposed mice to S. aureus and within hours detected a major increase in both the number and size of fat cells at the